NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
1.040
+0.040 (4.00%)
At close: Feb 13, 2026, 4:00 PM EST
0.9806
-0.0590 (-5.71%)
After-hours: Feb 13, 2026, 7:27 PM EST
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 17 employees as of December 31, 2024. The number of employees decreased by 1 or -5.56% compared to the previous year.
Employees
17
Change (1Y)
-1
Growth (1Y)
-5.56%
Revenue / Employee
n/a
Profits / Employee
-$509,294
Market Cap
34.73M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 17 | -1 | -5.56% |
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Werewolf Therapeutics | 39 |
| Atara Biotherapeutics | 38 |
| Quince Therapeutics | 36 |
| Jasper Therapeutics | 27 |
| Actinium Pharmaceuticals | 25 |
| Lantern Pharma | 24 |
| Outlook Therapeutics | 17 |
| Atossa Therapeutics | 15 |
NRSN News
- 5 days ago - NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition - PRNewsWire
- 24 days ago - NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease - PRNewsWire
- 5 weeks ago - World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB - PRNewsWire
- 7 weeks ago - NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study - PRNewsWire
- 2 months ago - NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 - PRNewsWire
- 2 months ago - NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS - PRNewsWire
- 3 months ago - NeuroSense to Host Investor Webinar on December 8, 2025 - PRNewsWire
- 4 months ago - NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers - PRNewsWire